Researchers Reveal Another KRAS Inhibitor

Abstract Researchers have developed a KRAS inhibitor, BI-2852, that inhibits ERK phosphorylation and reduces proliferation of KRAS-mutant cancer cells. A drug based on the molecule may be effective in patients who don't respond to the KRASG12C inhibitors currently in clinical trials.